XMD8-92 | CAS#1234480-50-2 | BMK1 Inhibitor

MedKoo Cat#: 407373 | Name: XMD8-92

Description:

WARNING: This product is for research use only, not for human or veterinary use.

XMD8-92 is an ERK5/BMK1 inhibitor and also BRD4 inhibitor. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. XMD8-92 blocks cellular BMK1 activation and significantly suppresses tumor growth in lung and cervical tumor models and is well tolerated in animals.

Chemical Structure

XMD8-92

CAS#1234480-50-2

Theoretical Analysis

MedKoo Cat#: 407373

Name: XMD8-92

CAS#: 1234480-50-2

Chemical Formula: C26H30N6O3

Exact Mass: 474.2379

Molecular Weight: 474.57

Elemental Analysis: C, 65.80; H, 6.37; N, 17.71; O, 10.11

Price and Availability

Size	Price	Availability
50mg	USD 350.00	2 Weeks
100mg	USD 600.00	2 Weeks
250mg	USD 1,150.00	2 Weeks
500mg	USD 1,950.00	2 Weeks
1g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

XMD8-92; XMD-8-92; XMD 8-92; XMD892; XMD-892; XMD 892.

IUPAC/Chemical Name

2-[[2-ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one

InChi Key

QAPAJIZPZGWAND-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H30N6O3/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29)

SMILES Code

O=C1N(C)C2=CN=C(NC3=CC=C(N4CCC(O)CC4)C=C3OCC)N=C2N(C)C5=CC=CC=C15

Appearance

White to beige solid powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 474.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Xiao H, Wang A, Shuai W, Qian Y, Wu C, Wang X, Yang P, Sun Q, Wang G, Ouyang L, Sun Q. A first-in-class selective inhibitor of ERK1/2 and ERK5 overcomes drug resistance with a single-molecule strategy. Signal Transduct Target Ther. 2025 Feb 20;10(1):70. doi: 10.1038/s41392-025-02169-z. PMID: 39979271; PMCID: PMC11842588. 2: Aoki-Utsubo C, Kameoka M, Deng L, Hanafi M, Dewi BE, Sudarmono P, Wakita T, Hotta H. Statins enhance extracellular release of hepatitis C virus particles through ERK5 activation. Microbiol Immunol. 2024 Oct;68(10):359-370. doi: 10.1111/1348-0421.13166. Epub 2024 Jul 29. PMID: 39073705. 3: Wang X, ShiYang X, Ma W, Wu X, Lu Y. Extracellular signal-regulated protein kinase 5 modulates the spindle assembly to coordinate the oocyte meiotic maturation. Theriogenology. 2024 Sep 15;226:335-342. doi: 10.1016/j.theriogenology.2024.06.028. Epub 2024 Jun 27. PMID: 38959844. 4: Tubita A, Menconi A, Lombardi Z, Tusa I, Esparís-Ogando A, Pandiella A, Gamberi T, Stecca B, Rovida E. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma. Am J Pathol. 2024 Aug;194(8):1581-1591. doi: 10.1016/j.ajpath.2024.03.015. Epub 2024 May 3. PMID: 38705382. 5: Liu Y, Niu R, Zhang X, Zhang B, Chen X, Guo J, Song S, Wang Y, Zhang H, Zhao Y. Metal-Organic Framework-Based Nanovaccine for Relieving Immunosuppressive Tumors via Hindering Efferocytosis of Macrophages and Promoting Pyroptosis and Cuproptosis of Cancer Cells. ACS Nano. 2024 May 14;18(19):12386-12400. doi: 10.1021/acsnano.4c01518. Epub 2024 May 3. PMID: 38699808. 6: Pan P, Ji D, Li Z, Meng X. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation. J Enzyme Inhib Med Chem. 2024 Dec;39(1):2287990. doi: 10.1080/14756366.2023.2287990. Epub 2023 Dec 7. PMID: 38062554; PMCID: PMC11792831. 7: Zhang Q, Gao X, Duan X, Liang H, Gao M, Dong D, Guo C, Huang L. Design, synthesis and SAR of novel 7-azaindole derivatives as potential Erk5 kinase inhibitor with anticancer activity. Bioorg Med Chem. 2023 Nov 15;95:117503. doi: 10.1016/j.bmc.2023.117503. Epub 2023 Oct 14. PMID: 37862935. 8: Abe JI, Imanishi M, Li S, Zhang A, Ko KA, Samanthapudi VSK, Lee LL, Bojorges AP, Gi YJ, Hobbs BP, Deswal A, Herrmann J, Lin SH, Chini EN, Shen YH, Schadler KL, Nguyen TH, Gupte AA, Reyes-Gibby C, Yeung SJ, Abe RJ, Olmsted-Davis EA, Krishnan S, Dantzer R, Palaskas NL, Cooke JP, Pownall HJ, Yoshimoto M, Fujiwara K, Hamilton DJ, Burks JK, Wang G, Le NT, Kotla S. An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circ Res. 2023 Jun 23;133(1):25-44. doi: 10.1161/CIRCRESAHA.122.322017. Epub 2023 Jun 2. PMID: 37264926; PMCID: PMC10357365. 9: Kanno H, Naito S, Obara Y, Ito H, Ichiyanagi O, Narisawa T, Kato T, Nagaoka A, Tsuchiya N. Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma. Int J Mol Sci. 2022 Jul 30;23(15):8448. doi: 10.3390/ijms23158448. PMID: 35955582; PMCID: PMC9369143. 10: Zhang S, Yu F, Che A, Tan B, Huang C, Chen Y, Liu X, Huang Q, Zhang W, Ma C, Qian M, Liu M, Qin J, Du B. Neuroendocrine Regulation of Stress-Induced T Cell Dysfunction during Lung Cancer Immunosurveillance via the Kisspeptin/GPR54 Signaling Pathway. Adv Sci (Weinh). 2022 May;9(13):e2104132. doi: 10.1002/advs.202104132. Epub 2022 Feb 27. PMID: 35224894; PMCID: PMC9069377. 11: Martviset P, Panrit L, Chantree P, Muhamad P, Na-Bangchang K. Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade. Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3633-3640. doi: 10.31557/APJCP.2021.22.11.3633. PMID: 34837922; PMCID: PMC9068173. 12: Tubita A, Lombardi Z, Tusa I, Lazzeretti A, Sgrignani G, Papini D, Menconi A, Gagliardi S, Lulli M, Dello Sbarba P, Esparís-Ogando A, Pandiella A, Stecca B, Rovida E. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21. Cancer Res. 2022 Feb 1;82(3):447-457. doi: 10.1158/0008-5472.CAN-21-0993. Epub 2021 Nov 19. PMID: 34799355; PMCID: PMC9397638. 13: Howell SJ, Lee CA, Batoki JC, Zapadka TE, Lindstrom SI, Taylor BE, Taylor PR. Retinal Inflammation, Oxidative Stress, and Vascular Impairment Is Ablated in Diabetic Mice Receiving XMD8-92 Treatment. Front Pharmacol. 2021 Aug 11;12:732630. doi: 10.3389/fphar.2021.732630. PMID: 34456740; PMCID: PMC8385489. 14: Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, Ucar DA, Miele L, Flaherty PT, Burow ME, Cavanaugh JE. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Transl Oncol. 2021 Jun;14(6):101046. doi: 10.1016/j.tranon.2021.101046. Epub 2021 Mar 21. PMID: 33761370; PMCID: PMC8020482. 15: Sun Y, Liang Y, Li Z, Xia N. Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway. Int J Endocrinol. 2020 Dec 9;2020:8821077. doi: 10.1155/2020/8821077. PMID: 33488706; PMCID: PMC7780226. 16: Lee GH, Park JS, Jin SW, Pham TH, Thai TN, Kim JY, Kim CY, Choi JH, Han EH, Jeong HG. Betulinic Acid Induces eNOS Expression via the AMPK-Dependent KLF2 Signaling Pathway. J Agric Food Chem. 2020 Dec 9;68(49):14523-14530. doi: 10.1021/acs.jafc.0c06250. Epub 2020 Nov 24. PMID: 33232606. 17: Zhang T, Zhao L, Zhang T, Wu W, Liu J, Wang X, Wan Y, Geng H, Sun X, Qian W, Yu D. Curcumin Negatively Regulates Cigarette Smoke-Induced Renal Cell Carcinoma Epithelial-Mesenchymal Transition Through the ERK5/AP-1 Pathway. Onco Targets Ther. 2020 Sep 29;13:9689-9700. doi: 10.2147/OTT.S265847. PMID: 33061449; PMCID: PMC7532894. 18: Ma C, Geng B, Zhang X, Li R, Yang X, Xia Y. Fluid Shear Stress Suppresses Osteoclast Differentiation in RAW264.7 Cells through Extracellular Signal- Regulated Kinase 5 (ERK5) Signaling Pathway. Med Sci Monit. 2020 Jan 8;26:e918370. doi: 10.12659/MSM.918370. PMID: 31914120; PMCID: PMC6977602. 19: Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. J Cell Biochem. 2020 Feb;121(2):1156-1168. doi: 10.1002/jcb.29350. Epub 2019 Aug 28. PMID: 31464004; PMCID: PMC6923606. 20: Yang C, Pang X, Chen W, Wang X, Lin G, Chu C, Zhang X, Deng X, Chen X, Liu G. Environmentally responsive dual-targeting nanotheranostics for overcoming cancer multidrug resistance. Sci Bull (Beijing). 2019 May 30;64(10):705-714. doi: 10.1016/j.scib.2019.04.019. Epub 2019 Apr 12. PMID: 36659653.